• 11 Feb 21

Psyence looking to be a major player in psychedelics using their federally licensed facilities

Psyence looking to be a major player in psychedelics using their federally licensed facilities

    • 44 views

 

Psyence BioMed (CSE: PSYG) CEO Jody Aufrichtig joined Steve Darling from Proactive to shares news about this newly listed company that is one of the few to have built and operate a Federally licensed commercial psilocybin cultivation and production facilities. Aufrichtig telling Proactive about that facility and how they plan to move forward with their Therapeutics, Production, Experience and Function

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

FTSE 100 sinks as Fed turns hawkish ahead of BoE rates decision; Serco rallies - Market Report

Companies: Severn Trent Plc

PyroGenesis Canada gives revenue guidance that more than doubles full year revenue in 2019

Companies: PyroGenesis Inc.

Executive interview - Fluence Corporation

Companies: Fluence Corporation Limited

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top